慢性閉塞性肺疾患治療薬の世界市場レポート、歴史と予測2018-2029年、企業別、主要地域別、タイプ別、用途別内訳データGlobal Chronic Obstructive Pulmonary Diseases Drugs Market Report, History and Forecast 2018-2029, Breakdown Data by Companies, Key Regions, Types and Application 慢性閉塞性肺疾患(COPD)は、気流閉塞を特徴とする慢性気管支炎および/または肺気腫であり、さらに肺冠や呼吸不全の一般的な慢性疾患に発展する可能性がある。それは有害なガスや有害な粒子の異常な炎症反応に関... もっと見る
※当ページの内容はウェブ更新時の情報です。
サマリー慢性閉塞性肺疾患(COPD)は、気流閉塞を特徴とする慢性気管支炎および/または肺気腫であり、さらに肺冠や呼吸不全の一般的な慢性疾患に発展する可能性がある。それは有害なガスや有害な粒子の異常な炎症反応に関連している。罹患率と致死率は非常に高く、40歳以上の世界的な罹患率は9%~10%と高い。QYResearch社のChronic Obstructive Pulmonary Diseases Drugsレポートでは、COVID-19とロシア・ウクライナ戦争が2022年の市場に影響を与えることが明らかにされています。世界の慢性閉塞性肺疾患治療薬市場は、2022年の100万米ドルから2029年には100万米ドルに達すると予測され、2023年から2029年の間に年平均成長率は%になると予測されています。病院と診療所からの需要が業界の主な促進要因である。 世界の医薬品市場は、2022年には1,475億米ドルとなり、今後6年間のCAGRは5%で成長する。医薬品市場には、化学医薬品と生物学的医薬品が含まれる。生物製剤は2022年に3810億ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造分野の開発に対する民間&政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要とする患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19パンデミックはワクチン開発とサプライチェーン・マネジメントの重要性を浮き彫りにし、製薬企業が公衆衛生の新たなニーズに機敏に対応する必要性をさらに強調している。 レポートの範囲 本レポートは、過去の分析(2018-2022年)と予測計算(2023-2029年)に基づき、読者が世界の慢性閉塞性肺疾患治療薬市場を多角的に包括的に理解し、読者の戦略と意思決定に十分な支援を提供することを目的としています。 レポート掲載企業、タイプ、用途、地域 企業別 サーカシア・ファーマシューティカルズ アストラゼネカ グラクソ・スミスクライン マイラン ベーリンガーインゲルハイム ファイザー アルミラル アボット・ラボラトリーズ ノバルティス テバ・ファーマシューティカル・インダストリーズ タイプ別セグメント 経口薬 注射剤 用途別セグメント 病院 クリニック その他 地域別 北米 アメリカ カナダ 欧州 ドイツ フランス 英国 イタリア ロシア 北欧諸国 アジア太平洋 中国 日本 韓国 東南アジア インド オーストラリア ラテンアメリカ メキシコ ブラジル 中東・アフリカ トルコ サウジアラビア アラブ首長国連邦 当レポートの各章では、読者が慢性閉塞性肺疾患治療薬市場をさらに理解するための詳細情報を提供しています: 第1章:歴史と予測期間(2018-2023年、2024-2029年)の世界と地域の市場規模とCAGR 第2章:2018年から2023年までの北米、欧州、アジア太平洋地域、ラテンアメリカ、中東およびアフリカにおける各タイプの製品タイプと収益分析。 第3章:2018年から2023年までの北米、欧州、アジア太平洋、ラテンアメリカ、中東およびアフリカにおける製品用途と各用途の収益分析。 第4章:企業競争状況、製品名企業の競争状況、収益、市場シェアとランキング、最新の開発計画、合併、買収情報などの詳細分析。 第5章:企業概要、企業の基本情報、慢性閉塞性肺疾患治療薬の紹介など慢性閉塞性肺疾患治療薬の各社の売上高とグロスマージン、最近の動向もこの部分に含まれています。 第6章から第10章:北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東、アフリカの国別レベル分析(収益別)。 第11章:市場力学、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク。 第12章:包括的調査に基づく慢性閉塞性肺疾患治療薬市場に関するQYResearch社の結論 第13章:QYResearchが採用した方法論とデータソース。 目次1 Market Overview of Chronic Obstructive Pulmonary Diseases Drugs1.1 Chronic Obstructive Pulmonary Diseases Drugs Market Overview 1.1.1 Chronic Obstructive Pulmonary Diseases Drugs Product Scope 1.1.2 Chronic Obstructive Pulmonary Diseases Drugs Market Status and Outlook 1.2 Global Chronic Obstructive Pulmonary Diseases Drugs Market Size Overview by Region 2018 VS 2022 VS 2029 1.3 Global Chronic Obstructive Pulmonary Diseases Drugs Market Size by Region (2018-2029) 1.4 Global Chronic Obstructive Pulmonary Diseases Drugs Historic Market Size by Region (2018-2023) 1.5 Global Chronic Obstructive Pulmonary Diseases Drugs Market Size Forecast by Region (2024-2029) 1.6 Key Regions, Chronic Obstructive Pulmonary Diseases Drugs Market Size (2018-2029) 1.6.1 North America Chronic Obstructive Pulmonary Diseases Drugs Market Size (2018-2029) 1.6.2 Europe Chronic Obstructive Pulmonary Diseases Drugs Market Size (2018-2029) 1.6.3 Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Market Size (2018-2029) 1.6.4 Latin America Chronic Obstructive Pulmonary Diseases Drugs Market Size (2018-2029) 1.6.5 Middle East & Africa Chronic Obstructive Pulmonary Diseases Drugs Market Size (2018-2029) 2 Chronic Obstructive Pulmonary Diseases Drugs Market by Type 2.1 Introduction 2.1.1 Oral Medicine 2.1.2 Injection Medicine 2.2 Global Chronic Obstructive Pulmonary Diseases Drugs Market Size by Type: 2018 VS 2022 VS 2029 2.2.1 Global Chronic Obstructive Pulmonary Diseases Drugs Historic Market Size by Type (2018-2023) 2.2.2 Global Chronic Obstructive Pulmonary Diseases Drugs Forecasted Market Size by Type (2024-2029) 2.3 Key Regions Market Size by Type 2.3.1 North America Chronic Obstructive Pulmonary Diseases Drugs Revenue Breakdown by Type (2018-2029) 2.3.2 Europe Chronic Obstructive Pulmonary Diseases Drugs Revenue Breakdown by Type (2018-2029) 2.3.3 Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Revenue Breakdown by Type (2018-2029) 2.3.4 Latin America Chronic Obstructive Pulmonary Diseases Drugs Revenue Breakdown by Type (2018-2029) 2.3.5 Middle East and Africa Chronic Obstructive Pulmonary Diseases Drugs Revenue Breakdown by Type (2018-2029) 3 Chronic Obstructive Pulmonary Diseases Drugs Market Overview by Application 3.1 Introduction 3.1.1 Hospital 3.1.2 Clinic 3.1.3 Others 3.2 Global Chronic Obstructive Pulmonary Diseases Drugs Market Size by Application: 2018 VS 2022 VS 2029 3.2.1 Global Chronic Obstructive Pulmonary Diseases Drugs Historic Market Size by Application (2018-2023) 3.2.2 Global Chronic Obstructive Pulmonary Diseases Drugs Forecasted Market Size by Application (2024-2029) 3.3 Key Regions Market Size by Application 3.3.1 North America Chronic Obstructive Pulmonary Diseases Drugs Revenue Breakdown by Application (2018-2029) 3.3.2 Europe Chronic Obstructive Pulmonary Diseases Drugs Revenue Breakdown by Application (2018-2029) 3.3.3 Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Revenue Breakdown by Application (2018-2029) 3.3.4 Latin America Chronic Obstructive Pulmonary Diseases Drugs Revenue Breakdown by Application (2018-2029) 3.3.5 Middle East and Africa Chronic Obstructive Pulmonary Diseases Drugs Revenue Breakdown by Application (2018-2029) 4 Chronic Obstructive Pulmonary Diseases Drugs Competition Analysis by Players 4.1 Global Chronic Obstructive Pulmonary Diseases Drugs Market Size by Players (2018-2023) 4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Chronic Obstructive Pulmonary Diseases Drugs as of 2022) 4.3 Date of Key Players Enter into Chronic Obstructive Pulmonary Diseases Drugs Market 4.4 Global Top Players Chronic Obstructive Pulmonary Diseases Drugs Headquarters and Area Served 4.5 Key Players Chronic Obstructive Pulmonary Diseases Drugs Product Solution and Service 4.6 Competitive Status 4.6.1 Chronic Obstructive Pulmonary Diseases Drugs Market Concentration Rate 4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles 5.1 Circassia Pharmaceuticals 5.1.1 Circassia Pharmaceuticals Profile 5.1.2 Circassia Pharmaceuticals Main Business 5.1.3 Circassia Pharmaceuticals Chronic Obstructive Pulmonary Diseases Drugs Products, Services and Solutions 5.1.4 Circassia Pharmaceuticals Chronic Obstructive Pulmonary Diseases Drugs Revenue (US$ Million) & (2018-2023) 5.1.5 Circassia Pharmaceuticals Recent Developments 5.2 AstraZeneca 5.2.1 AstraZeneca Profile 5.2.2 AstraZeneca Main Business 5.2.3 AstraZeneca Chronic Obstructive Pulmonary Diseases Drugs Products, Services and Solutions 5.2.4 AstraZeneca Chronic Obstructive Pulmonary Diseases Drugs Revenue (US$ Million) & (2018-2023) 5.2.5 AstraZeneca Recent Developments 5.3 GlaxoSmithKline 5.3.1 GlaxoSmithKline Profile 5.3.2 GlaxoSmithKline Main Business 5.3.3 GlaxoSmithKline Chronic Obstructive Pulmonary Diseases Drugs Products, Services and Solutions 5.3.4 GlaxoSmithKline Chronic Obstructive Pulmonary Diseases Drugs Revenue (US$ Million) & (2018-2023) 5.3.5 Mylan Recent Developments 5.4 Mylan 5.4.1 Mylan Profile 5.4.2 Mylan Main Business 5.4.3 Mylan Chronic Obstructive Pulmonary Diseases Drugs Products, Services and Solutions 5.4.4 Mylan Chronic Obstructive Pulmonary Diseases Drugs Revenue (US$ Million) & (2018-2023) 5.4.5 Mylan Recent Developments 5.5 Boehringer Ingelheim 5.5.1 Boehringer Ingelheim Profile 5.5.2 Boehringer Ingelheim Main Business 5.5.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Diseases Drugs Products, Services and Solutions 5.5.4 Boehringer Ingelheim Chronic Obstructive Pulmonary Diseases Drugs Revenue (US$ Million) & (2018-2023) 5.5.5 Boehringer Ingelheim Recent Developments 5.6 Pfizer 5.6.1 Pfizer Profile 5.6.2 Pfizer Main Business 5.6.3 Pfizer Chronic Obstructive Pulmonary Diseases Drugs Products, Services and Solutions 5.6.4 Pfizer Chronic Obstructive Pulmonary Diseases Drugs Revenue (US$ Million) & (2018-2023) 5.6.5 Pfizer Recent Developments 5.7 Almirall 5.7.1 Almirall Profile 5.7.2 Almirall Main Business 5.7.3 Almirall Chronic Obstructive Pulmonary Diseases Drugs Products, Services and Solutions 5.7.4 Almirall Chronic Obstructive Pulmonary Diseases Drugs Revenue (US$ Million) & (2018-2023) 5.7.5 Almirall Recent Developments 5.8 Abbott Laboratories 5.8.1 Abbott Laboratories Profile 5.8.2 Abbott Laboratories Main Business 5.8.3 Abbott Laboratories Chronic Obstructive Pulmonary Diseases Drugs Products, Services and Solutions 5.8.4 Abbott Laboratories Chronic Obstructive Pulmonary Diseases Drugs Revenue (US$ Million) & (2018-2023) 5.8.5 Abbott Laboratories Recent Developments 5.9 Novartis 5.9.1 Novartis Profile 5.9.2 Novartis Main Business 5.9.3 Novartis Chronic Obstructive Pulmonary Diseases Drugs Products, Services and Solutions 5.9.4 Novartis Chronic Obstructive Pulmonary Diseases Drugs Revenue (US$ Million) & (2018-2023) 5.9.5 Novartis Recent Developments 5.10 Teva Pharmaceutical Industries 5.10.1 Teva Pharmaceutical Industries Profile 5.10.2 Teva Pharmaceutical Industries Main Business 5.10.3 Teva Pharmaceutical Industries Chronic Obstructive Pulmonary Diseases Drugs Products, Services and Solutions 5.10.4 Teva Pharmaceutical Industries Chronic Obstructive Pulmonary Diseases Drugs Revenue (US$ Million) & (2018-2023) 5.10.5 Teva Pharmaceutical Industries Recent Developments 6 North America 6.1 North America Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2018-2029) 6.2 United States 6.3 Canada 7 Europe 7.1 Europe Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2018-2029) 7.2 Germany 7.3 France 7.4 U.K. 7.5 Italy 7.6 Russia 7.7 Nordic Countries 7.8 Rest of Europe 8 Asia-Pacific 8.1 Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Market Size by Region (2018-2029) 8.2 China 8.3 Japan 8.4 South Korea 8.5 Southeast Asia 8.6 India 8.7 Australia 8.8 Rest of Asia-Pacific 9 Latin America 9.1 Latin America Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2018-2029) 9.2 Mexico 9.3 Brazil 9.4 Rest of Latin America 10 Middle East & Africa 10.1 Middle East & Africa Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2018-2029) 10.2 Turkey 10.3 Saudi Arabia 10.4 UAE 10.5 Rest of Middle East & Africa 11 Chronic Obstructive Pulmonary Diseases Drugs Market Dynamics 11.1 Chronic Obstructive Pulmonary Diseases Drugs Industry Trends 11.2 Chronic Obstructive Pulmonary Diseases Drugs Market Drivers 11.3 Chronic Obstructive Pulmonary Diseases Drugs Market Challenges 11.4 Chronic Obstructive Pulmonary Diseases Drugs Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source 13.1 Methodology/Research Approach 13.1.1 Research Programs/Design 13.1.2 Market Size Estimation 13.1.3 Market Breakdown and Data Triangulation 13.2 Data Source 13.2.1 Secondary Sources 13.2.2 Primary Sources 13.3 Disclaimer 13.4 Author List
SummaryChronic obstructive pulmonary disease (COPD) is a chronic bronchitis and/or emphysema characterized by airflow obstruction, which can further develop into a common chronic disease of cor pulmona and respiratory failure.It is related to the abnormal inflammatory reaction of harmful gases and harmful particles. The morbidity rate and fatality rate are very high, and the global morbidity rate over 40 years old is as high as 9% ~ 10%. Table of Contents1 Market Overview of Chronic Obstructive Pulmonary Diseases Drugs1.1 Chronic Obstructive Pulmonary Diseases Drugs Market Overview 1.1.1 Chronic Obstructive Pulmonary Diseases Drugs Product Scope 1.1.2 Chronic Obstructive Pulmonary Diseases Drugs Market Status and Outlook 1.2 Global Chronic Obstructive Pulmonary Diseases Drugs Market Size Overview by Region 2018 VS 2022 VS 2029 1.3 Global Chronic Obstructive Pulmonary Diseases Drugs Market Size by Region (2018-2029) 1.4 Global Chronic Obstructive Pulmonary Diseases Drugs Historic Market Size by Region (2018-2023) 1.5 Global Chronic Obstructive Pulmonary Diseases Drugs Market Size Forecast by Region (2024-2029) 1.6 Key Regions, Chronic Obstructive Pulmonary Diseases Drugs Market Size (2018-2029) 1.6.1 North America Chronic Obstructive Pulmonary Diseases Drugs Market Size (2018-2029) 1.6.2 Europe Chronic Obstructive Pulmonary Diseases Drugs Market Size (2018-2029) 1.6.3 Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Market Size (2018-2029) 1.6.4 Latin America Chronic Obstructive Pulmonary Diseases Drugs Market Size (2018-2029) 1.6.5 Middle East & Africa Chronic Obstructive Pulmonary Diseases Drugs Market Size (2018-2029) 2 Chronic Obstructive Pulmonary Diseases Drugs Market by Type 2.1 Introduction 2.1.1 Oral Medicine 2.1.2 Injection Medicine 2.2 Global Chronic Obstructive Pulmonary Diseases Drugs Market Size by Type: 2018 VS 2022 VS 2029 2.2.1 Global Chronic Obstructive Pulmonary Diseases Drugs Historic Market Size by Type (2018-2023) 2.2.2 Global Chronic Obstructive Pulmonary Diseases Drugs Forecasted Market Size by Type (2024-2029) 2.3 Key Regions Market Size by Type 2.3.1 North America Chronic Obstructive Pulmonary Diseases Drugs Revenue Breakdown by Type (2018-2029) 2.3.2 Europe Chronic Obstructive Pulmonary Diseases Drugs Revenue Breakdown by Type (2018-2029) 2.3.3 Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Revenue Breakdown by Type (2018-2029) 2.3.4 Latin America Chronic Obstructive Pulmonary Diseases Drugs Revenue Breakdown by Type (2018-2029) 2.3.5 Middle East and Africa Chronic Obstructive Pulmonary Diseases Drugs Revenue Breakdown by Type (2018-2029) 3 Chronic Obstructive Pulmonary Diseases Drugs Market Overview by Application 3.1 Introduction 3.1.1 Hospital 3.1.2 Clinic 3.1.3 Others 3.2 Global Chronic Obstructive Pulmonary Diseases Drugs Market Size by Application: 2018 VS 2022 VS 2029 3.2.1 Global Chronic Obstructive Pulmonary Diseases Drugs Historic Market Size by Application (2018-2023) 3.2.2 Global Chronic Obstructive Pulmonary Diseases Drugs Forecasted Market Size by Application (2024-2029) 3.3 Key Regions Market Size by Application 3.3.1 North America Chronic Obstructive Pulmonary Diseases Drugs Revenue Breakdown by Application (2018-2029) 3.3.2 Europe Chronic Obstructive Pulmonary Diseases Drugs Revenue Breakdown by Application (2018-2029) 3.3.3 Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Revenue Breakdown by Application (2018-2029) 3.3.4 Latin America Chronic Obstructive Pulmonary Diseases Drugs Revenue Breakdown by Application (2018-2029) 3.3.5 Middle East and Africa Chronic Obstructive Pulmonary Diseases Drugs Revenue Breakdown by Application (2018-2029) 4 Chronic Obstructive Pulmonary Diseases Drugs Competition Analysis by Players 4.1 Global Chronic Obstructive Pulmonary Diseases Drugs Market Size by Players (2018-2023) 4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Chronic Obstructive Pulmonary Diseases Drugs as of 2022) 4.3 Date of Key Players Enter into Chronic Obstructive Pulmonary Diseases Drugs Market 4.4 Global Top Players Chronic Obstructive Pulmonary Diseases Drugs Headquarters and Area Served 4.5 Key Players Chronic Obstructive Pulmonary Diseases Drugs Product Solution and Service 4.6 Competitive Status 4.6.1 Chronic Obstructive Pulmonary Diseases Drugs Market Concentration Rate 4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles 5.1 Circassia Pharmaceuticals 5.1.1 Circassia Pharmaceuticals Profile 5.1.2 Circassia Pharmaceuticals Main Business 5.1.3 Circassia Pharmaceuticals Chronic Obstructive Pulmonary Diseases Drugs Products, Services and Solutions 5.1.4 Circassia Pharmaceuticals Chronic Obstructive Pulmonary Diseases Drugs Revenue (US$ Million) & (2018-2023) 5.1.5 Circassia Pharmaceuticals Recent Developments 5.2 AstraZeneca 5.2.1 AstraZeneca Profile 5.2.2 AstraZeneca Main Business 5.2.3 AstraZeneca Chronic Obstructive Pulmonary Diseases Drugs Products, Services and Solutions 5.2.4 AstraZeneca Chronic Obstructive Pulmonary Diseases Drugs Revenue (US$ Million) & (2018-2023) 5.2.5 AstraZeneca Recent Developments 5.3 GlaxoSmithKline 5.3.1 GlaxoSmithKline Profile 5.3.2 GlaxoSmithKline Main Business 5.3.3 GlaxoSmithKline Chronic Obstructive Pulmonary Diseases Drugs Products, Services and Solutions 5.3.4 GlaxoSmithKline Chronic Obstructive Pulmonary Diseases Drugs Revenue (US$ Million) & (2018-2023) 5.3.5 Mylan Recent Developments 5.4 Mylan 5.4.1 Mylan Profile 5.4.2 Mylan Main Business 5.4.3 Mylan Chronic Obstructive Pulmonary Diseases Drugs Products, Services and Solutions 5.4.4 Mylan Chronic Obstructive Pulmonary Diseases Drugs Revenue (US$ Million) & (2018-2023) 5.4.5 Mylan Recent Developments 5.5 Boehringer Ingelheim 5.5.1 Boehringer Ingelheim Profile 5.5.2 Boehringer Ingelheim Main Business 5.5.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Diseases Drugs Products, Services and Solutions 5.5.4 Boehringer Ingelheim Chronic Obstructive Pulmonary Diseases Drugs Revenue (US$ Million) & (2018-2023) 5.5.5 Boehringer Ingelheim Recent Developments 5.6 Pfizer 5.6.1 Pfizer Profile 5.6.2 Pfizer Main Business 5.6.3 Pfizer Chronic Obstructive Pulmonary Diseases Drugs Products, Services and Solutions 5.6.4 Pfizer Chronic Obstructive Pulmonary Diseases Drugs Revenue (US$ Million) & (2018-2023) 5.6.5 Pfizer Recent Developments 5.7 Almirall 5.7.1 Almirall Profile 5.7.2 Almirall Main Business 5.7.3 Almirall Chronic Obstructive Pulmonary Diseases Drugs Products, Services and Solutions 5.7.4 Almirall Chronic Obstructive Pulmonary Diseases Drugs Revenue (US$ Million) & (2018-2023) 5.7.5 Almirall Recent Developments 5.8 Abbott Laboratories 5.8.1 Abbott Laboratories Profile 5.8.2 Abbott Laboratories Main Business 5.8.3 Abbott Laboratories Chronic Obstructive Pulmonary Diseases Drugs Products, Services and Solutions 5.8.4 Abbott Laboratories Chronic Obstructive Pulmonary Diseases Drugs Revenue (US$ Million) & (2018-2023) 5.8.5 Abbott Laboratories Recent Developments 5.9 Novartis 5.9.1 Novartis Profile 5.9.2 Novartis Main Business 5.9.3 Novartis Chronic Obstructive Pulmonary Diseases Drugs Products, Services and Solutions 5.9.4 Novartis Chronic Obstructive Pulmonary Diseases Drugs Revenue (US$ Million) & (2018-2023) 5.9.5 Novartis Recent Developments 5.10 Teva Pharmaceutical Industries 5.10.1 Teva Pharmaceutical Industries Profile 5.10.2 Teva Pharmaceutical Industries Main Business 5.10.3 Teva Pharmaceutical Industries Chronic Obstructive Pulmonary Diseases Drugs Products, Services and Solutions 5.10.4 Teva Pharmaceutical Industries Chronic Obstructive Pulmonary Diseases Drugs Revenue (US$ Million) & (2018-2023) 5.10.5 Teva Pharmaceutical Industries Recent Developments 6 North America 6.1 North America Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2018-2029) 6.2 United States 6.3 Canada 7 Europe 7.1 Europe Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2018-2029) 7.2 Germany 7.3 France 7.4 U.K. 7.5 Italy 7.6 Russia 7.7 Nordic Countries 7.8 Rest of Europe 8 Asia-Pacific 8.1 Asia-Pacific Chronic Obstructive Pulmonary Diseases Drugs Market Size by Region (2018-2029) 8.2 China 8.3 Japan 8.4 South Korea 8.5 Southeast Asia 8.6 India 8.7 Australia 8.8 Rest of Asia-Pacific 9 Latin America 9.1 Latin America Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2018-2029) 9.2 Mexico 9.3 Brazil 9.4 Rest of Latin America 10 Middle East & Africa 10.1 Middle East & Africa Chronic Obstructive Pulmonary Diseases Drugs Market Size by Country (2018-2029) 10.2 Turkey 10.3 Saudi Arabia 10.4 UAE 10.5 Rest of Middle East & Africa 11 Chronic Obstructive Pulmonary Diseases Drugs Market Dynamics 11.1 Chronic Obstructive Pulmonary Diseases Drugs Industry Trends 11.2 Chronic Obstructive Pulmonary Diseases Drugs Market Drivers 11.3 Chronic Obstructive Pulmonary Diseases Drugs Market Challenges 11.4 Chronic Obstructive Pulmonary Diseases Drugs Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source 13.1 Methodology/Research Approach 13.1.1 Research Programs/Design 13.1.2 Market Size Estimation 13.1.3 Market Breakdown and Data Triangulation 13.2 Data Source 13.2.1 Secondary Sources 13.2.2 Primary Sources 13.3 Disclaimer 13.4 Author List
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(データ解析)の最新刊レポートQYResearch 社の最新刊レポート本レポートと同じKEY WORD(breakdown data)の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/10/04 10:27 147.72 円 163.39 円 196.69 円 |